Drug
GSK706769
GSK706769 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
2
67%
Ph phase_2
1
33%
Phase Distribution
2
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Completed1
Terminated1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (66.7%)
Phase 21 (33.3%)
Trials by Status
completed133%
terminated133%
withdrawn133%
Recent Activity
0 active trials
Showing 3 of 3
withdrawnphase_2
A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients
NCT00979771
completedphase_1
GSK706769 Repeat Dose Study
NCT00711386
terminatedphase_1
GSK706769 A First Time in Human Study For Males and Females
NCT00539201
Clinical Trials (3)
Showing 3 of 3 trials
NCT00979771Phase 2
A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients
NCT00711386Phase 1
GSK706769 Repeat Dose Study
NCT00539201Phase 1
GSK706769 A First Time in Human Study For Males and Females
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3